dafabet sports betting

Our pipeline of next-generation therapeutics focuses on using novel science to generate unrivaled clinical outcomes. Every step of the way, we work closely with global regulatory dafabet live casinoagencies to ensure that the safety, efficacy and quality of our pain medications meet – and ideally exceed – standards.

PHASE 3

Cebranopadol

The first and only investigational dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor (dual-NMR) agonist

Cebranopadol offers a unique approach to pain biology modulation through its first-in-class mechanism: the dual-NMR agonist. Its profile has been well-characterized in more than 30 efficacy and safety clinical trials involving approximately 2,000 patients to date. Data from these studies show cebranopadol:

  • is potentially as effective at treating acute, chronic dafabet casino appand neuropathic pain as the most potent therapies on the market today.
  • has potential to not cause the detrimental side effects seen with opioids such as physical dependence and misuse​.
  • may have significantly lower risk of overdose from respiratory depression.
  • is well-tolerated and has simple, once-a-day dosing that will not require adjustment for food, renal or hepatic impairment, or tapering at the end of therapy.

Because of its unique mechanism of action, cebranopadol has the potential to significantly change the pain-relief landscape. Notably, the FDA has granted Fast Track Designation to cebranopadol for chronic low back pain. dafabet live casinoIf approved, this investigational therapy could become the first and only pain relief treatment with the demonstrated ability to provide efficacy equivalent to traditional single-receptor agents and significantly less potential for misuse or risk of physical dependence, addiction or overdose.

PHASE 2

TRN-261

A first-in-class analgesic in development for multiple indications within acute and chronic pain

TRN-261 is a peptide molecule that has been extensively studied clinically in non-pain indications and has shown strong potential to deliver effective pain relief across multiple acute and chronic types. By combining the molecule’dafabet casino apps novel pain mechanism and safety profile with our unique formulation capabilities, TRN-261 has the potential to be a breakthrough treatment for millions of patients.

Our mission is to bring transformative pain management solutions to patients suffering from acute, chronic and neuropathic pain.